Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know
Organon (OGN) has garnered significant investor attention, with its stock returning +1.1% over the past month, outperforming the S&P 500. The company's earnings estimates for the current and next fiscal years indicate a mixed outlook, with a Zacks Rank #3 (Hold) suggesting it may perform in line with the broader market. Organon also shows an "A" grade in valuation, indicating it might be trading at a discount compared to its peers.
Organon & Co highlights its women’s health focus as a standalone company
Organon & Co positions itself as a global women's health specialist after spinning off from a larger pharmaceutical group. The company strategically focuses on contraception, fertility, and established medicines to generate steady cash flows for reinvestment and innovation. Its diversified portfolio aims to balance specialized offerings with broadly used therapies, ensuring revenue stability and addressing unmet medical needs in women's health.
Can Organon & Co. (OGN)’s MIUDELLA Launch Become a Major Driver in Women’s Health Markets?
Organon & Co. (OGN) is expanding its presence in women's health with the upcoming launch of MIUDELLA, a new hormone-free copper IUD, and through an expanded partnership with Samsung Bioepis for a biosimilar therapy in Canada. Though the article notes the potential of OGN, it also suggests that some AI stocks offer greater promise for higher and quicker returns, highlighting a strong interest in AI investment opportunities.
Enterprise value to EBITDA forward of Organon & Co. – MUN:7XP
This article provides financial information for Organon & Co. (MUN:7XP), specifically focusing on its enterprise value to EBITDA forward. It details the company's financials on the Munich Stock Exchange, indicating market status and offering access to various financial data points and resources through TradingView.
Price to earnings forward of Organon & Co. – NYSE:OGN
This article provides the "Price to earnings forward" value for Organon & Co. (NYSE: OGN). It indicates the value is zero and notes that the market is currently closed with no trades. The content is presented within the context of financial data provided by TradingView.
Price to sales forward of Organon & Co. – NYSE:OGN
This article presents financial data for Organon & Co. (NYSE: OGN), specifically focusing on its price-to-sales forward metric. Although no specific values are provided in the content itself, the article indicates that this data is available and is part of a larger financial overview of the company on the TradingView platform. It highlights OGN as a pharmaceuticals major within the health technology sector.
Price to book forward of Organon & Co. – LSE:0A9W
This article provides a financial snapshot of Organon & Co. (LSE:0A9W) focusing on its price-to-book forward ratio. It briefly mentions that the market is closed with no trades. The content is primarily a data presentation page from TradingView.
Organon marks 5 years of advancing health through medicines, solutions, partnerships
Organon is celebrating its fifth anniversary, marking a milestone in its mission to expand healthcare access, advance education, and strengthen partnerships. The company emphasizes its commitment to women's health, believing that prioritizing it benefits families and communities. Organon also highlights its efforts in diversity and inclusion, with employees celebrating Pride Month under the theme "We All Belong."
Organon & Co. Actuals & Estimates (NYSE:OGN)
This article provides a comprehensive overview of Organon & Co. (NYSE: OGN) stock, including current price, historical performance, analyst forecasts, and financial data. It covers actual and estimated earnings, revenue, dividends, market capitalization, and volatility, offering insights for potential investors.
Organon & Co stock hits 52-week high at $13.49
Organon & Co. (OGN) stock reached a 52-week high of $13.49, reflecting a 36% increase over the past year and significant gains in recent months. Despite this positive momentum and an InvestingPro analysis suggesting the stock is undervalued, the company recently reported first-quarter results that missed Wall Street expectations, with adjusted EPS and revenue falling short and Women's Health revenue declining. Organon is actively expanding its product offerings through licensing agreements and expanded indications for its biosimilars.
Organon & Co. Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Organon & Co. - OGN
Kahn Swick & Foti, LLC (KSF) is investigating the proposed sale of Organon & Co. (NYSE: OGN) to Sun Pharmaceutical Industries Limited, where shareholders are set to receive $14.00 per share. KSF aims to determine if this consideration and the underlying process are adequate, or if the Company is undervalued. Shareholders are invited to contact KSF to discuss their legal rights if they believe the transaction undervalues Organon.
Organon puts two Prolia, Xgeva biosimilars on sale in Canada
Organon Canada, in collaboration with Shanghai Henlius Biotech, Inc., has launched two denosumab biosimilars, BILDYOS® and TUZEMTY®, in Canada. These biosimilars are versions of PROLIA and XGEVA, used for treating osteoporosis and bone complications associated with cancer, and are now available for all indications of the reference products. This launch expands Organon's biosimilars portfolio in Canada to eight products across five therapeutic areas, aiming to improve treatment accessibility and reduce healthcare costs.
Organon secures global licensing deal for MIUDELLA copper IUD
Organon has secured a global licensing agreement with Sebela Pharmaceuticals for MIUDELLA, a hormone-free copper intrauterine device that is 99% effective. This deal grants Organon exclusive international distribution rights, expanding long-acting reversible birth control options for women. The company plans to launch the product in the U.S. in late 2026 through a risk management program.
Organon wins rights to first U.S. hormone-free copper IUD in 40 years
Organon has completed a licensing agreement for MIUDELLA®, Sebela Pharmaceuticals' hormone-free copper intrauterine device (IUD), marking the first such device introduced in the U.S. in over 40 years. MIUDELLA, approved by the FDA in February 2025 and expected to be commercially available in late 2026, offers 99% effectiveness for up to three years. The agreement enhances Organon's contraception portfolio, providing women with a new long-acting reversible birth control option, supported by a Risk Evaluation and Mitigation Strategy (REMS) program to ensure proper insertion.
Organon Completes Agreement to License MIUDELLA®, Sebela Pharmaceuticals’ Hormone-Free Intrauterine Device
Organon has finalized a global licensing agreement with Sebela Pharmaceuticals for MIUDELLA®, a hormone-free, copper intrauterine device (IUD). This FDA-approved device is the first of its kind in over 40 years, offers 99% effectiveness for up to three years, and is anticipated to be commercially available in late 2026. The agreement strengthens Organon's contraception portfolio by adding a new long-acting reversible option for women, with MIUDELLA® being distributed through a restricted REMS program to ensure proper insertion.
Organon and Samsung Bioepis Expand Agreement to Commercialize PYZCHIVA
Organon and Samsung Bioepis have expanded their agreement to commercialize PYZCHIVA (ustekinumab), a biosimilar referencing STELARA, in Canada, bringing their collaboration to six biosimilars. PYZCHIVA is indicated for conditions like chronic plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis, and is expected to launch in Canada in 2026. This expansion aims to enhance access to affordable biologic medicines and reinforce the financial stability of the Canadian healthcare system.
Samsung Bioepis, Organon expand Stelara biosimilar partnership to Canada
Samsung Bioepis and Organon have expanded their partnership, granting Organon commercialization rights in Canada for Pyzchiva, Samsung Bioepis' biosimilar of Stelara (ustekinumab). This addition brings their collaborative biosimilar portfolio in Canada to six products. The agreement aims to enhance healthcare system sustainability by increasing access to more affordable biologic medicines for conditions like psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis, with Pyzchiva expected to launch in Canada in 2026.
Organon and Samsung Bioepis Expand Agreement to Commercialize PYZCHIVA
Organon and Samsung Bioepis have expanded their collaboration to commercialize PYZCHIVA® (ustekinumab), a biosimilar referencing STELARA®, in Canada. This agreement grants Organon exclusive commercial rights for PYZCHIVA® in Canada, increasing their biosimilar portfolio together to six products across immunology, oncology, and dermatology. The launch of PYZCHIVA® is anticipated in 2026, aiming to enhance access to more affordable biologic medicines and support the Canadian healthcare system.
Samsung Bioepis and Organon Expand Agreement to Commercialize PYZCHIVA®, a Biosimilar Referencing STELARA® in Canada
Samsung Bioepis and Organon have expanded their commercialization agreement in Canada to include PYZCHIVA®, a biosimilar referencing STELARA® for various inflammatory conditions. This agreement deepens their collaboration to six biosimilars across immunology, oncology, and dermatology. Organon will hold commercial rights in Canada, while Samsung Bioepis will manage development, manufacturing, and regulatory responsibilities.
Organon and Samsung Bioepis Expand Agreement to Commercialize PYZCHIVA®
Organon and Samsung Bioepis have expanded their development and commercialization agreement, granting Organon commercialization rights in Canada for PYZCHIVA®, Samsung Bioepis’s biosimilar referencing STELARA® (ustekinumab). This expands their Canadian biosimilar portfolio to six products, including those for immunology, oncology, and dermatology. PYZCHIVA® is expected to launch in Canada in 2026, aiming to provide more affordable treatment options for conditions like plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis.
Organon, Samsung Bioepis add sixth biosimilar for Canada
Organon and Samsung Bioepis have expanded their collaboration, granting Organon commercialization rights in Canada for PYZCHIVA®, Samsung Bioepis’s biosimilar referencing STELARA®. This addition brings their joint Canadian biosimilar portfolio to six products, covering immunology, oncology, and dermatology, with PYZCHIVA® expected to launch in 2026. The partnership aims to enhance access to affordable biologic medicines and support the Canadian healthcare system by providing treatment options for conditions like psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Simulations Plus, Inc. (Nasdaq – SLP), Roku, Inc. (Nasdaq – ROKU), TruBridge, Inc. (Nasdaq – TBRG), Organon & Co. (NYSE – OGN)
Brodsky & Smith is investigating potential breaches of fiduciary duties by the Boards of Simulations Plus, Inc. (SLP), Roku, Inc. (ROKU), TruBridge, Inc. (TBRG), and Organon & Co. (OGN). These investigations concern whether the proposed acquisition prices for each company provide fair value to shareholders. Investors are encouraged to contact Brodsky & Smith for discussions regarding these investigations.
Sun Pharma agrees $11.75bn acquisition of Organon
Sun Pharmaceutical Industries Limited is set to acquire US drugmaker Organon & Co for $11.75 billion in an all-cash transaction. This acquisition aims to strengthen Sun Pharma’s position in established brands, diversify its revenue streams, and expand its global footprint, particularly in women's health and biosimilars. The deal, expected to close in early 2027, will create a combined entity that ranks among the top 25 global pharmaceutical companies.
Organon (OGN) director receives 17.8K phantom stock units as compensation
Organon & Co. director Cynthia M. Patton received 17,857.143 phantom stock units as compensation under the company's Non-Employee Director Savings Plan. These units, economically equivalent to common stock and valued at $13.44 each, will be settled in cash after her service concludes. This grant increases her total phantom stock holdings to 81,141.129 units, including previous dividend reinvestments.
Organon (OGN) director Shalini Sharp receives 17,857 phantom stock units as cash-settled award
Organon & Co. director Shalini Sharp has received 17,857.143 phantom stock units as part of her routine compensation, granted under the company's Non-Employee Director Savings Plan. These units are economically equivalent to Organon common stock at $13.44 per unit and will be paid in cash after her termination of service. Following this grant, her total phantom stock holdings amount to 81,495.885 units, including those acquired through dividend reinvestment.
Organon (OGN) director receives phantom stock award, lifting holdings above 81,000 units
Organon & Co. (OGN) director Rochelle B. Lazarus was granted 17,857.143 phantom stock units at a reference price of $13.44 per unit, significantly increasing her total holdings to 81,141.135 phantom stock units. These units, which are economically equivalent to common stock, were awarded under the Organon Non-Employee Director Savings Plan and will be settled in cash upon her departure from the board. The grant was reported in a Form 4 filing, indicating a compensation-related transaction rather than a market purchase or sale.
Organon (OGN) director awarded 17,857 phantom stock units under savings plan
Organon & Co. director Gayle Helene D was granted 17,857 phantom stock units on June 12, 2026, with an assigned value of $13.44 per unit. These units, which are economically equivalent to one share of Organon common stock, are payable in cash under the Non-Employee Director Savings Plan upon the termination of her board service. Following this award, her total holdings now amount to 81,141.134 phantom stock units, including those acquired through previous dividend reinvestments.
Organon & Co stock hits 52-week high at 13.48 USD
Organon & Co (OGN) stock has reached a new 52-week high of $13.48, marking a 33.76% increase over the past year due to strong investor confidence. This comes despite the company reporting first-quarter earnings that missed Wall Street expectations, with adjusted EPS and revenue both falling short, attributed to unfavorable pricing and declines in Women’s Health products. However, the FDA’s expanded approval for Organon’s TOFIDENCE biosimilar provides a positive development.
Organon & Co. Announces Results of 2026 Annual Meeting and Approves Incentive Stock Plan in Form 8-K Filing
Organon & Co. announced the results of its 2026 Annual Meeting, where shareholders approved an Amended and Restated 2021 Incentive Stock Plan, increasing available shares for issuance by 8,000,000. Key outcomes included the election of ten directors, approval of executive compensation, and ratification of PricewaterhouseCoopers LLP as the independent auditor. This move is intended to attract and retain talent through equity compensation, though investors are advised to consider potential share dilution.
Private Management Group Inc. Acquires 1,204,979 Shares of Organon & Co. $OGN
Private Management Group Inc. increased its stake in Organon & Co. (NYSE:OGN) by 38.3% in the fourth quarter, purchasing 1,204,979 additional shares to bring its total holding to 4,347,073 shares valued at approximately $31.2 million. Organon & Co. shares are trading near their 52-week high, despite the company recently reporting earnings below expectations. Analysts currently have a consensus "Reduce" rating for the stock.
Organon (NYSE: OGN) holders back amended 2021 incentive plan adding 8M shares
Organon & Co. shareholders approved an amended and restated 2021 Incentive Stock Plan at their Annual Meeting on June 9, 2026, increasing the shares available for equity awards by 8,000,000. Approximately 77% of outstanding shares were present or by proxy, and all director nominees were elected. This action expands the company's capacity to offer equity-based incentives to employees and other participants.
Organon & Co. (NYSE:OGN) Sets New 1-Year High - Still a Buy?
Organon & Co. (NYSE:OGN) recently hit a new 52-week high of $13.48, despite having previously reported mixed quarterly results and missing EPS and revenue estimates. Analyst sentiment has improved with several upgrades and raised price targets, though the overall consensus remains cautious with a "Reduce" rating and an average price target of $11.40. The company also announced a small quarterly dividend, and insider buying along with significant institutional ownership are noted as supportive factors.
Organon & Co stock hits 52-week high at 13.48 USD
Organon & Co (OGN) stock has reached a new 52-week high of $13.48, reflecting a 33.76% increase over the past year and strong investor confidence. Despite this, the company recently reported first-quarter earnings and revenue that missed Wall Street expectations, attributed to unfavorable pricing and product mix, particularly in Women's Health and Nexplanon sales. However, the FDA did approve expanded indications for Organon's biosimilar TOFIDENCE.
Brandes Investment Partners LP Has $4.35 Million Stock Holdings in Organon & Co. $OGN
Brandes Investment Partners LP significantly increased its stake in Organon & Co. by 46.7% in Q4, acquiring 193,064 additional shares, bringing its total holdings to 606,499 shares valued at $4.35 million. Insider activity also saw SVP Lynette Holzbaur double her ownership with a purchase of 26,448 shares. Despite some analysts raising price targets, the stock maintains an average "Reduce" rating with a consensus price target of $11.40.
Organon wins US approval to widen use of arthritis biosimilar drug
Organon has received FDA approval to expand the use of its biosimilar drug, Tofidence, which is similar to Roche's Actemra. The expanded approval includes treating severe cytokine release syndrome in certain cancer patients and COVID-19 patients requiring breathing support. This move is expected to alleviate the financial strain of high-cost biologics on the U.S. healthcare system.
Organon & Co. (OGN) is a trending stock: Facts to know before betting on it
This article identifies Organon & Co. (OGN) as a currently trending stock. It suggests that investors research key facts about the company before making any investment decisions.
SBI May Commit $1 Billion to Support Sun Pharma’s $12 Billion Organon Acquisition
The State Bank of India (SBI) is reportedly considering financing up to $1 billion for Sun Pharmaceutical Industries Ltd.'s $12 billion acquisition of Organon & Co. This move would mark a significant step, making it one of the largest outbound acquisitions by an Indian company and highlighting SBI's growing role in global M&A financing, partly due to recent regulatory changes by the RBI. The potential involvement underscores India's ambition for global expansion and could allow Indian companies greater access to domestic financing for international deals.
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Organon & Co. (OGN)
Brodsky & Smith is investigating Organon & Co. (OGN) for potential breaches of fiduciary duty by its Board of Directors regarding the proposed sale to Sun Pharmaceutical Industries Limited for $14.00 per share. The law firm is examining whether the transaction offers fair value to shareholders and if a fair process was followed. Shareholders are invited to contact Brodsky & Smith to discuss the legal implications without obligation.
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Organon & Co. (OGN)
Brodsky & Smith is investigating potential claims against the Board of Directors of Organon & Co. (OGN) regarding its sale to Sun Pharmaceutical Industries Limited for $14.00 per share. The investigation focuses on whether Organon's Board breached its fiduciary duties by failing to conduct a fair process and ensuring fair value for shareholders. Shareholders are invited to contact Brodsky & Smith for more information.
Organon (OGN) to be Acquired by Sun Pharma for $14.00 Cash per Share
Organon & Co. has agreed to be acquired by Sun Pharmaceutical Holdings USA, Inc. for $14.00 per share in cash, a deal recommended by Organon's Board of Directors. The acquisition is subject to stockholder approval, regulatory clearances, and customary conditions, with closing expected in early 2027. Sun Pharma USA will fund the acquisition through cash on hand and a committed senior secured bridge facility.
OGN - Organon & Co Stock Price and Quote
This page provides a detailed financial overview of Organon & Co (OGN), including its stock price, key financial metrics, recent news filings, analyst ratings, and insider trading activity. It highlights the company's performance, significant events like acquisition offers from Sun Pharma, and executive information.
Hanmi Pharma partners with Organon to export combination therapies to Southeast Asia
Hanmi Pharmaceutical has signed a supply agreement with Organon to export three combination medicines for cardiovascular and respiratory therapeutic areas to Malaysia and the Philippines. This partnership expands their collaboration in Southeast Asia, with Organon handling marketing, distribution, and sales while Hanmi supplies the finished products. The agreement is set to support Hanmi's commercial expansion in the rapidly growing Southeast Asian pharmaceutical market, particularly as demand for combination therapies rises due to increasing chronic diseases.
Hanmi Pharma partners with Organon to export combination therapies to Southeast Asia
Hanmi Pharmaceutical has signed an agreement with Organon to supply three combination medicines for cardiovascular and respiratory therapeutic areas to Malaysia and the Philippines. Organon will handle marketing and sales in these markets, with potential for future expansion. This partnership aims to leverage the rapidly growing pharmaceutical market in Southeast Asia, particularly for combination therapies.
Organon & Co(OGN) Stock Options Chain | Quotes & News
This page provides information regarding Organon & Co (OGN) stock, including its options chain, quotes, and related news. It serves as a resource for investors interested in tracking the company's financial data and market activity.
Organon to supply Hanmi’s 3 combo drugs in Malaysia, Philippines
Hanmi Pharmaceutical has signed a supply agreement with Organon to export three combination drugs for cardiovascular and respiratory treatments to Malaysia and the Philippines. This partnership aims to expand both companies' presence in Southeast Asia, a rapidly growing pharmaceutical market, by leveraging Hanmi's broad portfolio of combination drugs and Organon's marketing and distribution networks. The companies plan phased regulatory approvals and launches, reflecting their shared goal of improving access to essential medicines in the region.
Organon to supply Hanmi’s 3 combo drugs in Malaysia, Philippines
Hanmi Pharmaceutical has signed a supply agreement with Organon to export three of its combination drugs for cardiovascular and respiratory treatment to Malaysia and the Philippines. Organon will manage the marketing, distribution, and sales in these markets, expanding the companies' partnership in Southeast Asia. This collaboration aims to enhance healthcare access and treatment options in a rapidly growing pharmaceutical market.
OGN Stock Price, Quote & Chart | ORGANON & CO (NYSE:OGN)
ORGANON & CO (NYSE:OGN) stock is currently trading at $13.43, up 0.07% today, with significant gains of 19.27% over the past month and 54.55% over the past year. The company received a strong technical rating of 9/10 from ChartMill but a moderate fundamental rating of 5/10 due to concerns about its financial health. Analysts have an average price target of $11.02 for OGN, suggesting a potential decrease of 17.97% in the next year.
Hanmi Pharmaceutical Partners with Organon to Export Combination Therapies to Southeast Asia
Hanmi Pharmaceutical has signed an agreement with global healthcare company Organon to export three combination medicines for cardiovascular and respiratory therapeutic areas to Malaysia and the Philippines. Organon will handle marketing, distribution, and sales in these markets, while Hanmi will supply the finished products. This partnership aims to expand Hanmi's commercial presence in Southeast Asia and improve access to essential medicines in the region.
Hanmi Pharmaceutical Partners with Organon to Export Combination Therapies to Southeast Asia
Hanmi Pharmaceutical has announced a partnership with Organon to export three of its combination therapies for cardiovascular and respiratory conditions to Malaysia and the Philippines. This agreement strengthens Hanmi's presence in the rapidly growing Southeast Asian pharmaceutical market, with Organon handling marketing, distribution, and sales. Both companies aim to expand treatment options and improve access to medicines in the region.
Hanmi Pharmaceutical Partners with Organon to Export Combination Therapies to Southeast Asia
Hanmi Pharmaceutical has partnered with Organon to supply three combination medicines for cardiovascular and respiratory conditions to Malaysia and the Philippines. Organon will handle marketing, distribution, and sales, aiming to expand treatment options in Southeast Asia's growing pharmaceutical market. This collaboration builds on Hanmi's strategy for global expansion and addresses the increasing demand for combination therapies for chronic diseases in the region.
